HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.

Abstract
Despite impressive improvements in neurosurgical techniques, radiation and chemotherapy during the past few years, little progress has been made in the treatment of malignant gliomas. Recently, the efficacy of suicide gene therapy based on replication-competent retroviral (RCR) vectors as delivery vehicles for the therapeutic gene has been described in the treatment of experimental cancer, including gliomas. In this study, we have thus critically evaluated a panel of human and rodent glioma/glioblastoma cell lines (U-87MG, U-118MG, LN-18, LN-229, 8-MG-BA, 42-MG-BA, A-172, T-98G, UVW, C6, 9L, G-26, GL-261, Tu-2449, Tu-9648) with respect to RCR virus vector spread, sensitivity towards the cytosine deaminase (CD)/5-flurocytosine (5-FC)/5-flurouracil (5-FU) suicide system, and orthotopic growth characteristics in mice to identify suitable preclinical animal models for the development of a glioblastoma gene therapy. Rapid virus spread was observed in eight out of nine human cell lines tested in vitro. As expected, only CD-expressing cells became sensitive to 5-FC, due to their ability to convert the prodrug in its toxic form, 5-FU. All LD(50) values were within the range of concentrations obtained in human body fluids after conventional antifungal 5-FC administration. In addition, a significant bystander effect was observed in all human glioma cell lines tested. Injection of the RCR vector into pre-established orthotopic mouse tumor xenografts revealed substantial infection and virus spread of tumor tissue from most cell types.
AuthorsJuraj Hlavaty, Gerrit Jandl, Melissa Liszt, Helga Petznek, Marielle König-Schuster, Jenny Sedlak, Monika Egerbacher, Jakob Weissenberger, Brian Salmons, Walter H Günzburg, Matthias Renner
JournalJournal of neuro-oncology (J Neurooncol) Vol. 102 Issue 1 Pg. 59-69 (Mar 2011) ISSN: 1573-7373 [Electronic] United States
PMID20623247 (Publication Type: Comparative Study, Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Prodrugs
  • Flucytosine
  • Cytosine Deaminase
  • Fluorouracil
Topics
  • Animals
  • Brain Neoplasms (drug therapy, genetics, pathology)
  • Bystander Effect
  • Cytosine Deaminase (administration & dosage, genetics, metabolism)
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Flucytosine (therapeutic use)
  • Fluorouracil (therapeutic use)
  • Genes, Transgenic, Suicide
  • Genetic Therapy
  • Genetic Vectors
  • Glioblastoma (drug therapy, genetics, pathology)
  • Humans
  • Mice
  • Mice, Nude
  • Mice, SCID
  • Prodrugs (therapeutic use)
  • Retroviridae (genetics)
  • Transduction, Genetic
  • Tumor Cells, Cultured
  • Virus Replication (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: